Safety and efficacy
Numerous reports of ICD implantation in children suggest that the implantation procedure itself has very little risk, with a mortality rate at implant of less than 1% [1]. However, several questions remain about growth and lead longevity. The author's experience at Mattel Children's Hospital in 12 patients younger than 12 years has shown no loss of lead position or function at 2 years of follow-up and no loss of lead function in two patients age 9 and 10 years after more than 5 years of follow-up. Large series of prospective data are needed to evaluate lead longevity accurately in pediatric patients, and the influence of lead type, implant technique, and projected growth.
The efficacy of ICDs in the pediatric population has also not been studied in a systematic way. Data from adult populations in randomized trials have shown a clear advantage to device therapy when compared with conventional medical therapy. There are numerous large, randomized trials, many of which were ended early because of reduced mortality in the ICD group. MADIT (Multicenter Autonomic Defibrillator Implantation Trial) and MADIT II, MUSTT (Multicenter Unsustained Tachycardia Trial), and AVID (Antiarrhythmics Versus Implantable Defibrillators) [2, 3] all compared device therapy with conventional therapy in at-risk populations. Initial studies focused on the highest risk groups, including cardiac arrest survivors and patients with documented ventricular arrhythmias. Subsequent studies focused on lower risk populations, like the MADIT II trial, which focused on patients with an ejection fraction less than 30% and no other indication for an ICD. Despite the lower risk of the population, there was still a 30% reduction in all-cause mortality. In these same studies, insertion techniques were also examined. The subclavian route of insertion resulted in more complications than the cephalic vein route-46 (14%) of 339 versus six (4%) of 135, P = 0.005-as did the abdominal versus pectoral generator site-31 (13%) of 238 versus 17 (6%) of 291, P < 0.02. Most dislodgments and system infections tended to occur in the 3 months after implantation, whereas lead fractures continued to occur throughout follow-up. The applicability of these trials to pediatric populations is not clear. However, it is clear that a properly functioning ICD is the intervention most likely to prevent mortality in at-risk populations.
The largest study of pediatric patients was a retrospective review of patients retrieved from manufacturer's databases [1]. This study examined the indications and outcomes for 125 patients younger than 21 years who had received an ICD. In that study, 68% of patients had received an appropriate shock. The 5-year survival rate was 90%. There was also a 20% incidence of inappropriate or spurious discharges. The authors concluded, "The patterns of ICD discharge observed in young patients and, thus, inferred risk of recurrent life threatening arrhythmias are similar to those of adult survivors of SCD [sudden cardiac death]," implying that pediatric patients are likely to have the same degree of benefit from ICD implantation as adult patients. A smaller study of the frequency of complications in pediatric patients found a higher incidence of infection, lead migration, and lead fracture in pediatric patients compared with adults [4] .
Indications for an implantable cardioverter-defibrillator in pediatric patients
Limited experience and an absence of randomized clinical trials have made the assessment of appropriate indications for ICD implants in pediatric patients an imposs i b l e t a s k . T h e 1 9 9 8 A m e r i c a n C o l l e g e o f Cardiology/American Heart Association Guidelines for Implantation of Pacemakers and Antiarrhythmia Devices [5] failed to make any specific recommendations about indications for pediatric patients. The report did state that "indications for ICD therapy for pediatric patients are similar to adults." The report also suggests that "a family history of sudden death may influence the decision to use an ICD in a pediatric patient." The diseases for which ICDs are implanted in pediatric patients include postoperative congenital heart disease, hypertrophic cardiomyopathy, long QT syndrome, dilated cardiomyopathy, idiopathic ventricular fibrillation, and Kawasaki disease with coronary artery involvement. There are anecdotal reports and retrospective reviews of the use of ICDs in all these conditions; however, there are no randomized trials for any of these diagnoses, even in patients older than 21 years. Data available on the use of ICDs in the most common of these diagnoses are reviewed individually.
Postoperative congenital heart disease
The incidence of sudden death after surgery for congenital heart disease is approximately 0.9 per 1000 patient years [6] . A diagnosis of congenital heart disease accounts for approximately 20% of ICD implantations in the pediatric population, with transposition of the great arteries the most frequent single diagnosis. Aortic stenosis and Tetralogy of Fallot are also common diagnoses. The risk of sudden death after repair of Tetralogy of Fallot has been studied extensively, and several risk factors have been identified. The risk of sudden death is 1.5% to 2.5% per decade, with high-grade ventricular ectopy, right ventricular volume or pressure overload, and QRS duration longer than 180 ms indicating increased risk. However, at present there are no indicators of risk predictive enough to warrant ICD implantation in the absence of symptoms or documented arrhythmia. This is also the case for other forms of congenital heart disease. The role of noninvasive surveillance and invasive electrophysiology studies in determining at-risk populations is also unclear, but asymptomatic arrhythmia and positive invasive electrophysiology studies are both predictors of higher risk and play a role in evaluating this population [7] . The effectiveness of ICD implantation in this population appears to be quite good, especially in patients with normal ventricular function [3] .
Hypertrophic cardiomyopathy
There has been extensive investigation of the risk of sudden death in hypertrophic cardiomyopathy and the use of ICDs in this population [8] . Significant risk factors include a family history of sudden death, wall thickness greater than 2 cm [9] , and history of syncope or resuscitated cardiac arrest. Maron et al. [8] reported multicenter retrospective data in 128 patients with hypertrophic cardiomyopathy who had undergone ICD implantation, including 19 pediatric patients. Of the 128 patients included in the study, 85 (66%) had ICD implants because of a history of syncope or family history of sudden death (primary prevention). In the remaining 43 (34%), the indication for implant was resuscitated sudden death or sustained ventricular tachycardia (secondary prevention). During an average follow-up period of 3.1 years, 23% of the patients experienced an appropriate discharge, whereas 25% experienced inappropriate discharges. There were only two deaths, both with intractable ventricular arrhythmia despite appropriate ICD discharges in the setting of severe ventricular dysfunction.
Long QT syndrome
Congenital long QT syndrome has also been the subject of intense investigation, but despite a detailed understanding of the molecular basis for most cases of long QT syndrome, a complete understanding of the factors lead-ing to sudden death is still lacking. The risk of sudden death in patients with symptomatic long QT syndrome is estimated to be 20% in the first year after diagnosis and 50% in the first 10 years after diagnosis, without treatment. ␤-Adrenergic blocking therapy has been shown to reduce the risk of cardiac events in this population. However, ␤-blocker therapy alone does not prevent sudden death in all patients. Patients with a history of aborted or resuscitated sudden death have a 14% risk of a second arrest within 5 years [10] . Groh et al. [11] reported retrospective data on the use of ICDs in long QT syndrome. Patients in this study were identified through a search of manufacturer's databases and subsequent surveys sent to implanting physicians. In that series, data on 35 patients were available for analysis. Eleven patients (55%) were in the pediatric age group. During an average follow-up of 31 months, 21 patients (60%) received appropriate ICD discharges, with two patients receiving repetitive appropriate discharges, requiring increased ␤-blocker therapy in one and dual chamber pacing in the other. There were no deaths during follow-up.
Advances in technology likely to influence use of implantable cardioverter-defibrillators in the pediatric population
There have been numerous advances in ICD technology during the last decade that are likely to influence the use of ICDs in the pediatric population. Although device size would be an obvious factor likely to influence the use of these devices in smaller patients, a steady decrease in the size of the devices and the leads has failed to influence the proportion of pediatric patients receiving devices compared with adults [12] . A major concern in the use of these devices in children has been inappropriate discharges for sinus tachycardia. The availability of dual chamber devices with atrial sensing has allowed devices to prevent spurious shocks when 1:1 AV conduction is present at rates consistent with sinus rhythm. Refinements in morphology discrimination, onset criteria, and supraventricular tachycardia recognition are also likely to reduce the incidence of inappropriate shocks. This reduction is important in younger patients who will likely require device therapy for more than several decades.
Conclusions
The use of implantable cardioverter-defibrillators in pediatric patients is becoming an increasingly important mode of therapy for preventing sudden death. Available data show a high rate of appropriate discharges, presumably representing aborted sudden death, with a low complication rate. Data from studies in adult patients show a clear superiority of ICD therapy compared with conventional medical therapy, making a device a more logical intervention in at-risk pediatric patients.
The diseases most commonly associated with sudden death in the pediatric population are inherited; thus, a family history of sudden death may be an important indication for ICD therapy. As the cost of the devices and the risks associated with the implant procedure fall, the threshold for considering ICD therapy in pediatric patients is also likely to fall.
Defining at-risk populations is the next challenge for physicians caring for these patients. Multicenter, randomized trials in pediatric patients are lacking, but data from studies in adults suggest that use of medical therapy to prevent sudden death is unlikely to compare favorably with ICD therapy. Thus, the lifelong risk of sudden death in any given patient must be weighed against the risk of the implant procedure and subsequent risk of device failure or replacement. Issues of lead longevity and venous access are also likely to become important factors in pediatric patients. Analyzing the influence of these factors in randomized trials will require decades of follow-up, making it unlikely that randomized prospective data will be available in the near future to help guide the clinician faced with a patient at risk for sudden death.
